Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,494 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Not listed Phase 2 Interventional Results available

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04742400
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
tolebrutinib 60mg, tolebrutinib 120mg
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 20, 2026, 10:59 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Stepped Care Approach to Treating Tobacco Use in Rural Veterans

NCT04501016
View directory record Official record
Conditions
Tobacco Cessation
Interventions
Tailored behavioral counseling, Tobacco cessation pharmacotherapy
Behavioral · Drug
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

NCT04319926
View directory record Official record
Conditions
Healthy
Interventions
lidocaine topical system 1.8%, lidocaine patch 5%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

NCT05024747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
Drug
Lead sponsor
HALEON
Industry
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 20, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention

NCT02511236
View directory record Official record
Conditions
Smoking Cessation
Interventions
Group Cognitive Behavioral Therapy, General Health Education, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Coral Gables, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 20, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

NCT00330564
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
Interventions
SU011248
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 20, 2026, 10:59 AM EDT
Not listed Phase 2 Interventional

Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation

NCT02008448
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Pulmonary vein isolation, Linear Lesion Ablation, BT injection
Procedure · Drug
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 20, 2026, 10:59 AM EDT
Completed No phase listed Observational Results available

Safety and Performance Study of the FAST-FIX FLEX System for Meniscal Repairs and Meniscal Transplantations

NCT04903106
View directory record Official record
Conditions
Meniscus Tear
Interventions
FAST-FIX FLEX Meniscal Repair System
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

NCT02465606
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Encino, California • Granada Hills, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy Adults

NCT02486016
View directory record Official record
Conditions
Peer Review, Research
Interventions
Duragesic reference fentanyl TDS, Apotex generic fentanyl TDS, Mylan generic fentanyl TDS
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 20, 2026, 10:59 AM EDT
Not yet recruiting Phase 2 Interventional

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

NCT07285993
View directory record Official record
Conditions
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions
18F-FAPI-74, 18F-FDG, PET/CT
Drug · Procedure
Lead sponsor
Randy Yeh
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Recruiting Phase 4 Interventional

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

NCT06966362
View directory record Official record
Conditions
Veterans, Tobacco Use Disorder, Cigarette Smoking, Tobacco Dependence
Interventions
Motivation-Phase Varenicline, Motivation-Phase Nicotine Mini-Lozenge, Cessation-Phase Combination Nicotine Replacement Therapy (NRT), Cessation-Phase Varenicline, Motivation-Phase Counseling, Cessation-Phase Counseling
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Not yet recruiting Phase 4 Interventional

Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial

NCT07835555
View directory record Official record
Conditions
Tobacco Use Disorder/Cigarette Smoking, HIV
Interventions
nicotine patch, nicotine gum, nicotine lozenge, varenicline, bupropion, Multi-target Contingency Management, Teamlet booster
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
5
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • Jersey City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

PRecision Interventions for SMoking in the SCCS

NCT03521141
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
Drug · Genetic · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment

NCT01372254
View directory record Official record
Conditions
Cigarette Smoking, Drug Use
Interventions
Standard Treatment, BAD-AS, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 4 Interventional

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

NCT00569751
View directory record Official record
Conditions
Cardiovascular Disease, de Novo Coronary Lesions
Interventions
TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
53
States / cities
Scottsdale, Arizona • Bakersfield, California • Rancho Mirage, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 20, 2026, 10:59 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Radiographic Progression of Infiltrated Caries Lesions In-vivo

NCT01496456
View directory record Official record
Conditions
Dental Caries
Interventions
Resin infiltration, Caries management
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

A Randomized Study of Sulindac in Oral Premalignant Lesions

NCT00299195
View directory record Official record
Conditions
Leukoplakia, Oral, Benign Neoplasms
Interventions
sulindac, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 20, 2026, 10:59 AM EDT
Recruiting Phase 2 Interventional

L19IL2/TNF in Patients With Basal Cell Carcinoma

NCT07227870
View directory record Official record
Conditions
Locally Advanced Basal Cell Carcinoma
Interventions
L19IL2/L19TNF
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Tampa, Florida • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 10:59 AM EDT